1. Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

3. Learning Objectives

4. Introduction

5. Treatment Selection in NSCLC

7. Nivolumab vs Chemotherapy in Second-Line Treatment of NSCLC

8. Additional PD-1/PD-L1 and CTLA-4 Agents in ≥ Second-Line Treatment of NSCLC

9. Case Study 1: NSCLC 74-Year-Old Male Patient

10. Benefits of Immunotherapy vs Chemotherapy

11. Case Study 1: NSCLC (cont)

12. New Lesions and Treatment Decisions

13. Pseudoprogression and Immunotherapy Treatment

14. Early Results of Immunotherapy in Frontline Treatment of NSCLC

15. Case Study 2: Squamous NSCLC 77-Year-Old Female Patient

16. Immunotherapies and Adverse Events

17. Immunotherapies and Adverse Events

18. Biomarker Testing and Immunotherapy

19. Conclusions and Future Perspectives

20. Abbreviations

21. Abbreviations (cont)

22. References

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)